Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17765413 | 0.77 | PLAU (0.38) | IDO1CYP11B2PLAUTSHR | |
| SCHEMBL151547 | 0.71 | IDO1 (0.38) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL22554804 | 0.71 | CYP19A1 (0.39) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL1702930 | 0.71 | CYP19A1 (0.39) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL6143052 | 0.71 | IDO1 (0.43) | IDO1PLAU | |
| SCHEMBL23457245 | 0.71 | IDO1 (0.38) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL2853835 | 0.71 | IDO1 (0.38) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL583647 | 0.71 | IDO1 (0.38) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL1040813 | 0.71 | IDO1 (0.38) | IDO1KDM4EL3MBTL1CYP19A1CYP11B1 | |
| SCHEMBL9532783 | 0.69 | DRD3 (0.39) | IDO1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9676679-B2 | Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators | The Florida State University Research Foundation, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | The Florida State University Research Foundation, Inc | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | OR51E2, OR10J3, ORC3 | IDO1 1939/4885KDM4E 3226/4885L3MBTL1 3114/4885 |
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | IDO1 1089/4885KDM4E 4286/4885L3MBTL1 4769/4885 |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | AOC3, OR51E2, AOC2 | IDO1 4535/4885KDM4E 1836/4885L3MBTL1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.